On Monday at the Institute of Medical Science and SUM Hospital in Bhubaneswar the human trial of the much-awaited coronavirus vaccine began.

In the ICMR, one of the 12 centers selected by the Indian Council of Medical Research (ICMR) for phase one, and in phase two of the process, an official at the facility said the much awaited trial of BBV152 COVID-9 vaccine or covaxin began.

Dr. E Venkat Rao, principal investigator for a trial phase, told PTI that Covaxin, which Bharat Biotech develops, had been administered to a number of selected people who had volunteered to take part in the crucial trial.

Such volunteers were rigorously tested as part of this process, and then administered by the Drugs Controller General of India (DCGI) in compliance with the vaccination protocols strictly.

The development is as the country’s coronaviral cases reached 14 lakh points on Monday, following a one-day leap of 49,931 COVID-19 cases. The death toll has risen to 32,771, with 708 deaths a day.

In the nation there are 4,85,114 active cases, 9,17,567 patients recovered. According to the results, the recovery rate is 63.92%.

This is the fifth consecutive day in which cases of COVID-19 have grown by over 45,000. Until 26 July, a total of 1,68,06,803 samples had been tested, according to the Indian Council of Medical Research (ICMR). 

Was this helpful?

0 / 5 0

Latest news

  • No comments yet.
  • Add a comment

    For latest news updates, Subscribe now!

    Enter your email address:

    Delivered by FeedBurner